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Abstract
Background: Next-generation sequencing (NGS) has revolutionized genetic research and offers enormous potential
for clinical application. Sequencing the exome has the advantage of casting the net wide for all known coding
regions while targeted gene panel sequencing provides enhanced sequencing depths and can be designed to
avoid incidental findings in adult-onset conditions. A HaloPlex panel consisting of 180 genes within commonly
altered chromosomal regions is available for use on both the Ion Personal Genome Machine® (PGMTM) and MiSeq
platforms to screen for causative mutations in these genes.
Methods: We used this Haloplex ICCG panel for targeted sequencing of 15 patients with clinical presentations
indicative of an abnormality in one of the 180 genes. Sequencing runs were done using the Ion 318 Chips on the Ion
Torrent PGM. Variants were filtered for known polymorphisms and analysis was done to identify possible disease-causing
variants before validation by Sanger sequencing. When possible, segregation of variants with phenotype in family
members was performed to ascertain the pathogenicity of the variant.
Results: More than 97 % of the target bases were covered at >20×. There was an average of 9.6 novel variants per
patient. Pathogenic mutations were identified in five genes for six patients, with two novel variants. There were
another five likely pathogenic variants, some of which were unreported novel variants.
Conclusions: In a cohort of 15 patients, we were able to identify a likely genetic etiology in six patients (40 %).
Another five patients had candidate variants for which further evaluation and segregation analysis are ongoing. Our
results indicate that the HaloPlex ICCG panel is useful as a rapid, high-throughput and cost-effective screening tool for
170 of the 180 genes. There is low coverage for some regions in several genes which might have to be supplemented
by Sanger sequencing. However, comparing the cost, ease of analysis, and shorter turnaround time, it is a good
alternative to exome sequencing for patients whose features are suggestive of a genetic etiology involving one of the
genes in the panel.
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Background
Congenital disorders comprise conditions present at
birth or those that developed during infancy or early
childhood. Presentations include structural abnormalities,
neuromuscular disorders, developmental delay, and intel-
lectual disability which collectively affect more than 10 %
of children. The European Surveillance of Congenital
Anomalies (EUROCAT) reported the prevalence of major
congenital anomalies to be about 2.4 % of live births [1],
while the Center for Disease Control and Prevention (CDC)
reported 3.3 % for birth defects [2]. The prevalence of devel-
opmental disabilities is reported to be 13.9 % in the USA [3].
Less than half of these disorders have an identifiable
cause such as aneuploidy, metabolic disorder, maternal
infection, parental exposure to teratogenic agents, or
intrapartum events. The remaining cases are thought to
have a genetic etiology such as submiscroscopic chromo-
somal abnormalities or rare single/multiple nucleotide
changes. The former can be detected by using chromo-
somal microarray analysis (CMA) which is now the rec-
ommended first-tier test for children with dysmorphism,
multiple congenital anomalies, developmental delay/
intellectual disability, and/or autism spectrum disorder
[4]. Although CMA is more sensitive than conventional
karyotyping, the diagnostic yield for this group of disor-
ders is still only about 20 % in multiple studies [5–7].
Genetic causes for the rest are likely due to small deletions
and insertions, balanced translocations involving gene dis-
ruptions, and point mutations which cannot be detected
by commonly used CMA platforms.
With massively parallel sequencing, many regions and
even the entire genome can be interrogated simultan-
eously to identify such mutations. Although the cost of
whole genome sequencing has become progressively
lower in the last few years, data analysis and interpret-
ation remain challenging. Due to the large number of
short-reads, the sequence data has to be mapped back to
the reference genome and filtered through known data-
bases to identify variants for each individual, leading to
long turnaround time from clinic testing to reporting.
There is also the issue of incidental findings unrelated to
the indication for testing and the American College of
Medical Genetics and Genomics (ACMG) have recom-
mended the reporting of pathogenic variants for 56
genes [8]. Subsequently, the ACMG recommended that
patients be given the choice of opting out of receiving
such information [9]. For these reasons, many laboratories
still use Sanger sequencing of single or a few genes when
there are known causal genes for the suspected disorders.
Exome sequencing can partly overcome the issue of
data throughput but not the possibility of incidental
findings. Targeted gene panels can address both by fo-
cusing on a set of relevant candidate genes with known
diagnostic yield, while providing cost-related advantage
as well as easier data analysis without the need for special-
ized computing infrastructure and expertise. The American
Society of Human Genetics (ASHG) also recommends that
gene testing should be limited to single genes or targeted
gene panels based on the clinical presentations of the
patient [10]. Compared to Sanger sequencing of single
genes, targeted gene panel sequencing has much
higher throughput, but each design needs to be evaluated
for coverage and sensitivity before being put to routine
clinical diagnostic use.
Among several pre-designed catalog panels for
pediatric congenital disorders, there is one comprising
180 genes located within chromosomal regions with a
high frequency of cytogenetic abnormalities in constitu-
tional disorders [11] according to publicly available data
from the International Collaboration for Clinical Genomics
(ICCG—previously known as International Standards for
Cytogenomic Arrays or ISCA) [12, 13]. To assess the
coverage and sensitivity of this ICCG gene panel for
high-throughput next-generation sequencing in congenital
disorders, we used the Ion Torrent PGM platform to




The patients were previously recruited under two separate
projects (CIRB Ref: 2007/831/F and 2010/238/F). Ap-
proval to conduct this sequencing study was provided by
the SingHealth Central Institutional Review Board (CIRB
Ref: 2013/798/F). All the subjects were minors, and writ-
ten informed consent had been obtained from the parents.
Study samples
The 15 patients were previously recruited from the hospi-
tal’s Genetics Clinics for testing of chromosomal imbalance
using human 400 K CGH arrays (Agilent Technologies
Inc., Santa Clara, USA). No significant pathogenic copy
number changes were identified in all 15. Inclusion criteria
include developmental delay/intellectual disability and
multiple congenital anomalies. Each patient had been
followed up and examined by a clinical geneticist. All of
them have clinical features suggestive of a disorder associ-
ated with one of the 180 genes, although the features may
not have been typical or completely fulfilled the clinical cri-
teria of a specific syndrome at the time of recruitment.
DNA extraction
Genomic DNA was manually extracted from peripheral
blood collected in EDTA tubes using the Gentra Pure-
gene Blood Kit (Qiagen Inc., Valencia, USA) according
to the manufacturer’s instructions. DNA quality and
quantity were measured on a Nanodrop Spectrophotom-
eter (Thermo Scientific, Wilmington, USA).
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Library construction, sequencing, and data analysis
Genomic DNA (225 ng gDNA) was digested with 16
different restriction enzymes at 37 °C for 30 min to cre-
ate a library of gDNA restriction fragments. Both ends
of the targeted fragments were selectively hybridized to
biotinylated probes from the HaloPlex ICCG panel (Agilent
Technologies Inc., Santa Clara, CA, USA), which resulted
in direct fragment circularization. During the 16-h
hybridization process, HaloPlex ION Barcodes and Ion
Torrent sequencing motifs were incorporated into the
Table 1 Summary of sequencing output and quality for each sample
Sample Reads Bases
Total Mapped On target Mean depth Aligned ≥Q20 On target Uniformitya
1 1,348,756 1,322,761 91.29 % 203.4 98.59 % 87.61 % 55.36 % 92.47 %
2 1,389,395 1,361,138 91.29 % 209.9 98.58 % 87.80 % 54.95 % 92.55 %
3 1,552,042 1,522,728 91.16 % 234.3 98.63 % 87.82 % 55.29 % 92.37 %
4 1,494,165 1,470,215 91.90 % 226.8 98.71 % 87.87 % 55.06 % 92.76 %
5 1,369,435 1,346,412 91.91 % 210.2 98.78 % 88.89 % 54.65 % 92.90 %
6 1,663,702 1,633,814 91.20 % 252.4 98.72 % 88.33 % 55.03 % 92.43 %
7 1,602,753 1,569,980 91.01 % 242.7 98.67 % 88.75 % 55.14 % 92.36 %
8 1,694,348 1,662,379 91.25 % 256.8 98.69 % 88.80 % 54.90 % 92.36 %
9 1,431,017 1,398,943 90.08 % 211.7 98.30 % 88.04 % 54.83 % 92.52 %
10 1,717,174 1,677,112 90.16 % 253.2 98.24 % 87.83 % 55.57 % 92.12 %
11 1,408,352 1,373,789 89.67 % 205.5 98.12 % 87.42 % 55.28 % 92.56 %
12 1,511,078 1,484,377 90.97 % 227.3 98.42 % 88.06 % 54.93 % 92.51 %
13 1,554,866 1,521,948 90.96 % 235.1 98.44 % 89.17 % 55.07 % 92.11 %
14 1,578,886 1,547,559 91.48 % 239.6 98.54 % 89.31 % 55.09 % 92.54 %
15 1,558,185 1,525,061 90.91 % 234.0 98.50 % 88.91 % 55.03 % 92.40 %
aPercentage of target bases covered by at least 0.2× the average base read length
Fig. 1 Percentage of bases at the different read depths
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Table 2 Mean coverage with highest and lowest number of
reads for target regions for each gene
Gene Mean Lowest Highest
1 ABCC8 338.07 81.92 786.09
2 ABCD1 169.66 12.56 411.39
3 ACSL4a 164.77 21.30 492.11
4 AFF2 214.46 36.76 580.05
5 ALX4 222.07 84.73 558.92
6 AP1S2a 135.94 38.59 325.08
7 APCa 179.90 3.73 406.62
8 AR 223.99 43.85 529.40
9 ATP7Aa 178.46 15.96 431.28
10 ATRX 158.16 10.57 441.01
11 AVPR2 212.24 91.24 401.30
12 BMP4a 277.08 184.26 355.73
13 BMPR1Aa 249.32 92.33 500.82
14 BMPR2 221.72 39.06 545.08
15 BRCA2a 226.44 69.62 659.97
16 BRWD3 158.01 1.94 403.65
17 BSND 281.21 166.64 426.50
18 BTKa 248.63 71.65 522.36
19 CACNA1C 313.63 70.18 681.23
20 CASK 174.65 3.07 469.39
21 CDKN1Ca 61.17 21.98 111.66
22 CFC1 0.00 0.00 0.06
23 CHD7a 238.95 6.00 491.12
24 CHD8a 241.14 3.17 571.36
25 CHM 138.15 0.00 424.06
26 CHRNA7 133.17 0.00 649.69
27 CLCNKAa 207.37 41.54 632.50
28 CLCNKBa 227.42 19.10 558.00
29 CNTN4a 258.10 74.48 742.09
30 COL2A1 311.23 28.83 762.32
31 COL4A5 145.99 6.30 492.06
32 CREBBP 307.73 66.01 682.75
33 CUL4Ba 148.17 35.09 399.12
34 CYP21A2 42.13 0.00 317.76
35 DCX 191.11 31.11 424.96
36 DHCR7a 356.18 73.73 715.42
37 DMRT1 317.71 99.58 526.08
38 DYMa 199.54 35.51 538.64
39 DYRK1A 238.22 56.46 539.50
40 EDNRBa 244.22 108.94 440.60
41 EHMT1 322.86 0.00 914.42
42 EMX2 191.49 89.92 367.85
43 EXT1 255.03 122.82 531.24
Table 2 Mean coverage with highest and lowest number of
reads for target regions for each gene (Continued)
44 EXT2 268.11 55.88 603.23
45 EYA1 259.46 9.39 471.54
46 F8 208.53 0.00 590.76
47 F9 194.99 29.24 362.11
48 FANCA 305.66 17.51 898.72
49 FANCBa 115.90 28.51 270.95
50 FBN1a 275.76 42.56 611.18
51 FGD1 232.34 56.74 586.70
52 FGFR1a 313.99 118.45 666.21
53 FLNAa 243.40 56.48 688.98
54 FMR1 156.86 48.89 329.36
55 FOXC1 93.65 76.19 114.03
56 FOXG1 96.79 77.95 125.85
57 FOXL2 93.73 75.81 114.31
58 FZD4 211.12 93.71 360.16
59 GATA3a 324.33 155.81 637.81
60 GATA4a 295.62 50.09 587.59
61 GDF5 155.05 113.49 212.75
62 GJB2a 249.56 200.76 298.70
63 GLA 214.53 82.27 473.23
64 GLI2 312.00 149.69 577.16
65 GLI3a 286.99 108.72 560.08
66 GPC3 216.44 42.47 424.44
67 GPC6 251.39 134.79 392.07
68 GPR56a 294.55 71.00 606.66
69 GRIA3 204.51 69.61 433.75
70 HBA1 50.15 0.00 182.69
71 HBA2 10.42 0.00 40.79
72 HCCSa 177.03 62.86 347.20
73 HNF1B 321.62 59.22 722.67
74 HOXD13 278.61 105.47 524.08
75 HPRT1 151.03 46.04 318.21
76 IDS 183.74 4.69 498.62
77 IKBKG 51.43 0.00 348.87
78 IRF6a 265.75 126.04 468.45
79 JAG1 308.99 57.19 644.27
80 KAL1 196.43 33.50 435.56
81 KCNJ1 341.18 200.92 557.14
82 KCNQ1 321.89 62.66 842.39
83 L1CAMa 238.10 33.83 531.65
84 LAMP2 161.71 16.59 374.76
85 LEMD3 162.74 55.42 325.70
86 LHX4 340.77 146.93 643.51
87 LMX1B 165.54 66.47 408.35
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Table 2 Mean coverage with highest and lowest number of
reads for target regions for each gene (Continued)
88 MECP2 116.40 21.60 224.22
89 MID1a 188.60 44.28 383.24
90 MITF 303.77 97.21 559.04
91 MSX1 148.47 85.95 232.61
92 MSX2 147.01 93.77 230.81
93 MTM1a 197.51 54.42 517.75
94 MYCNa 228.84 96.40 407.08
95 NDPa 237.17 92.91 444.75
96 NDUFV1 299.67 104.88 555.45
97 NF2 368.03 144.63 794.05
98 NHS 189.40 24.18 373.29
99 NIPBLa 172.28 15.79 382.14
100 NLGN4Xa 251.27 119.13 470.66
101 NOTCH2 281.99 0.00 642.59
102 NR5A1a 222.01 116.84 407.74
103 NRXN1a 225.80 21.56 577.97
104 NSD1a 261.44 86.24 500.38
105 OCA2a 321.02 106.42 685.92
106 OCRL 178.97 13.16 440.97
107 OFD1 171.17 58.00 394.13
108 OTC 190.78 1.46 562.10
109 OTX2 311.41 198.51 476.69
110 PAFAH1B1a 234.58 15.99 516.41
111 PAK3 181.03 47.33 405.32
112 PAX3 235.81 80.62 569.70
113 PAX6a 242.37 25.79 599.28
114 PAX9a 258.47 7.00 540.15
115 PGK1 252.23 95.17 614.74
116 PHEX 200.00 48.82 439.78
117 PHF6a 165.22 63.07 315.44
118 PIGB 205.86 19.26 539.76
119 PITX2a 283.28 122.96 548.91
120 PKD1 99.18 0.00 512.88
121 PKD2 225.02 47.45 475.99
122 PLP1 247.34 9.76 525.11
123 PREPLa 215.09 36.12 484.89
124 PRPS1 247.30 102.55 418.52
125 PTCH1 270.35 12.72 733.37
126 PTEN 150.42 22.31 371.28
127 PTPN11 267.28 7.24 610.72
128 RAI1a 343.75 101.17 648.66
129 RB1 131.02 14.38 388.44
130 RET 271.31 71.71 635.08
131 RPS19a 321.73 108.91 519.38
Table 2 Mean coverage with highest and lowest number of
reads for target regions for each gene (Continued)
132 RS1 222.95 115.25 327.74
133 RUNX2a 273.57 111.60 506.80
134 SALL1a 358.75 261.01 497.61
135 SALL4 275.10 113.08 406.79
136 SATB2a 308.41 180.72 485.31
137 SCN1A 184.22 17.84 385.17
138 SGCE 176.87 0.23 424.34
139 SH2D1A 221.35 64.88 432.85
140 SHANK3 244.90 12.74 621.93
141 SHH 161.98 64.47 259.27
142 SIX3 122.83 85.98 168.90
143 SLC12A1a 258.77 62.97 558.39
144 SLC12A3 280.89 56.97 814.03
145 SLC16A2 265.88 60.08 534.50
146 SLC3A1 226.04 90.48 481.54
147 SLC6A8 115.64 2.00 346.38
148 SLC9A6 140.59 40.48 373.83
149 SMAD4a 290.53 109.10 607.62
150 SOX2 195.01 156.36 240.25
151 SPINK1a 194.39 57.54 401.97
152 SRY 65.35 0.00 189.58
153 SYN1 211.18 33.53 488.47
154 SYNGAP1 209.23 41.07 495.34
155 TBCEa 274.69 89.15 774.41
156 TBX1a 281.13 28.78 628.34
157 TBX3 229.37 102.59 459.90
158 TBX5a 267.57 94.82 473.34
159 TCF4a 277.43 72.17 568.07
160 TCOF1 335.67 175.06 602.11
161 TGFBR1 211.80 1.52 479.34
162 TGFBR2 303.18 84.26 614.98
163 TGIF1 302.73 169.50 481.36
164 TIMM8A 166.52 37.46 370.74
165 TRPS1a 267.79 112.32 411.15
166 TSC1a 293.98 45.37 607.17
167 TSC2a 286.10 0.00 776.60
168 TWIST1 96.89 76.02 120.38
169 UPF3B 200.15 53.63 424.96
170 USH1C 283.03 38.50 767.39
171 VHL 130.75 57.24 269.80
172 WT1 335.43 112.21 654.89
173 XIAPa 132.08 31.85 278.12
174 ZDHHC9a 223.57 61.28 554.63
175 ZEB2a 261.68 97.71 474.05
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targeted fragments. Circularized target DNA-HaloPlex
probe hybrids containing biotin were then captured by
HaloPlex Magnetic Beads on the Agencourt SPRIPlate
Super magnet magnetic plate. DNA ligase was added to
close the nicks in the hybrids, and freshly-prepared NaOH
was used to elute the captured target libraries. The target
libraries were then amplified with 18 PCR cycles and
purified using AMPure XP beads. Amplicons ranging
from 150 to 550 bp were then quantified using an
Agilent BioAnalyzer High Sensitivity DNA Assay kit on
the 2100 Bioanalyzer to validate the enrichment of the
libraries. Library preparation took approximately 1½ days.
Equimolar amounts of four multiplexed bar-coded
libraries were pooled and clonally amplified by emulsion
PCR, using the Ion PGM Template OT2 200 Kit 9 (Life
Technologies, Carlsbad, CA, USA). The template-
positive Ion Sphere Particles (ISPs) were then enriched
with the Ion OneTouchTM ES and loaded on an Ion
318TM Chip v1. Four separate runs were performed for
the 15 samples, with one sample sequenced twice on
two different chips. Sequencing was carried out in the
Ion PGMTM System using the Ion PGMTM Sequencing
200 Kit v2 according to the manufacturer’s instructions
with 500 flow runs.
The data from the sequencing runs were analyzed
using the Torrent Suite v4.0.2 analysis pipeline, which
includes raw sequencing data processing (DAT process-
ing), splitting of the reads according to the barcode for
the individual sample output sequence, classification,
signal processing, base calling, read filtering, adapter
trimming, and alignment QC. Single-nucleotide poly-
morphisms (SNP), multi-nucleotide polymorphisms
(MNPs), insertions, and deletions were identified across
the targeted subset of the reference using a plug-in
Torrent Variant Caller (v4.0-r76860), with the param-
eter settings optimized for germ-line high frequency
variants and minimal false positive calls. The output
variant call format (VCF) file was then annotated through
the web-based user-interfaced GeneTalk (GeneTalk
GmbH, Berlin, Germany) and Ensembl Variant Effect
Predictor [14].
Sequence variants were compared with data in dbSNP,
1000 Genomes and Human Genome Mutation Database.
Variants not previously reported in healthy controls or
previously classified as pathogenic were evaluated for
coverage depth and also visually inspected using the In-
tegrative Genomics Viewer before validation by dideoxy
sequencing using standard protocol for BigDye® Termin-
ator v3.1 Cycle Sequencing Kit (Life Technologies,
Carlsbad, CA, USA). Segregation analysis was performed
when DNA from family members was available. Sequen-
cing was carried out on the Applied Biosystems® 3130
Genetic Analyzer (Life Technologies, Carlsbad, CA,
USA). In addition, SIFT (sift.bii.a-star.edu.sg) and Poly-
phen2 (genetics.bwh.harvard.edu/pph2) were used to check
the likely functional significance of missense variants for
clinical interpretation.
Results
An average of 790 Mb was generated per chip (range
748–828 Mb). Loading densities of the targeted sequen-
cing of four libraries (four samples were multiplexed in
each library) ranged from 75 to 81 %. The total number
of reads (usable sequence) ranged from 5.8 to 6.4 M,
and average read length ranged from 124 to 131 bp.
After filtering out polyclonal, low quality, and primer di-
mers, the percentage of usable reads ranged from 69 to
73 %. On average, each sample yielded 196 M bases
from 1.5 M reads (Table 1 and Fig. 1) from 58,670
amplicons with a mean read length of 128 bp. One sam-
ple was sequenced twice, with near identical output ob-
tained for both runs. The numbers of reads were
1,552,042 and 1,556,202 for total reads and 1,522,728
and 1,524,576 for mapped reads, and total numbers of
bases sequenced were 199,024,281 and 200,813,003.
Approximately 97.4 % of the reads were aligned to the
reference genome (hg19) and 91 % mapped to the target
regions, with average base coverage ranging from 203×
to 256× for individual samples. 97.7 % of the targets had
minimum read depth of 20×, 95.6 % at >50× and 88.2 %
at >100×. Full coverage was achieved for more than
95 % of targets in all 15 samples, and most (approxi-
mately 89.9 %) target bases did not show any bias to-
ward forward or reverse strand read alignment. The
average total coverage of all targeted bases was 95.7 % at
20× and 82.38 % at 100×. Coverage was also uniform
across all samples. More than 88 % of called bases had a
quality score of ≥Q20 (Table 1).
At the gene level, 137 of the 180 genes had mean
coverage of at least 20×, of which 99 had a mean of
>50× and 40 had a mean of >100× (Table 2). Despite the
high target region coverage, amplification failed for at
least 26 exons across the 180 genes. Thirteen genes
(CFC1, CHRNA7, CYP21A2, EHMT1, F8, HBA1, HBA2,
IKBKG, NOTCH2, PKD1, SGCE, SRY, TSC2) had at least
one region that was not amplified and therefore not
sequenced (lowest number of reads “0” in Table 2). The
sequencing coverage of CFC1, IKBKG, HBA1, and HBA2
Table 2 Mean coverage with highest and lowest number of
reads for target regions for each gene (Continued)
176 ZFPM2 211.09 6.00 393.25
177 ZIC1 228.52 127.92 369.74
178 ZIC2 128.92 29.81 320.70
179 ZIC3 202.01 120.08 320.90
180 ZIC4 291.25 127.92 616.00
aTarget regions do not include non-coding first exons
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was low with >50 % of these genes sequenced at >20×
(Table 3). The gene with the highest mean coverage was
SALL1 (358×). The poorest coverage was for CFC1.
Mean read depth for individual exons for three different
genes were shown in Figs. 2, 3, and 4.
Overall, 2326 single-nucleotide variants (SNVs) and 25
indels were identified in the 15 patients. These variants
identified from the Ion Reporter had an average coverage
of 595× and an average Qscore of 38. Variant annotation
indicated that 2203 were common variants present in
dbSNP and 1000 Genome Project databases. The number
of variants ranged from 154 to 175 per patient, with an
average of 9.6 novel variants each. Synonymous variants
were the most common.
Variants were prioritized for Sanger confirmation
based on the individual’s clinical presentations. Pathogenic
variants were confirmed in six patients. The identified
CHD7 (two patients), SHH,TCF4,TSC2, andMECP2 vari-
ants and the clinical features of these six patients are listed
in Table 4. Another five patients had candidate variants
Table 3 Percentage of coverage for each gene at 20×
ABCC8 100.00 % DMRT1 100.00 % HNF1B 100.00 % OTX2 100.00 % SLC16A2 100.00 %
ABCD1 100.00 % DYM 100.00 % HOXD13 100.00 % PAFAH1B1 100.00 % SLC3A1 100.00 %
ACSL4 100.00 % DYRK1A 100.00 % HPRT1 100.00 % PAK3 100.00 % SLC6A8 94.71 %
AFF2 100.00 % EDNRB 100.00 % IDS 89.40 % PAX3 100.00 % SLC9A6 100.00 %
ALX4 100.00 % EHMT1 99.47 % IKBKG 26.71 % PAX6 100.00 % SMAD4 100.00 %
AP1S2 100.00 % EMX2 100.00 % IRF6 100.00 % PAX9 99.61 % SOX2 100.00 %
APC 98.72 % EXT1 100.00 % JAG1 100.00 % PGK1 100.00 % SPINK1 100.00 %
AR 100.00 % EXT2 100.00 % KAL1 100.00 % PHEX 100.00 % SRY 100.00 %
ATP7A 100.00 % EYA1 100.00 % KCNJ1 100.00 % PHF6 100.00 % SYN1 100.00 %
ATRX 99.29 % F8 99.66 % KCNQ1 100.00 % PIGB 100.00 % SYNGAP1 100.00 %
AVPR2 100.00 % F9 100.00 % L1CAM 100.00 % PITX2 100.00 % TBCE 100.00 %
BMP4 100.00 % FANCA 100.00 % LAMP2 100.00 % PKD1 86.06 % TBX1 100.00 %
BMPR1A 100.00 % FANCB 100.00 % LEMD3 100.00 % PKD2 100.00 % TBX3 100.00 %
BMPR2 100.00 % FBN1 100.00 % LHX4 100.00 % PLP1 79.74 % TBX5 100.00 %
BRCA2 100.00 % FGD1 100.00 % LMX1B 100.00 % PREPL 100.00 % TCF4 100.00 %
BRWD3 99.43 % FGFR1 100.00 % MECP2 100.00 % PRPS1 100.00 % TCOF1 100.00 %
BSND 100.00 % FLNA 100.00 % MID1 100.00 % PTCH1 97.80 % TGFBR1 93.58 %
BTK 100.00 % FMR1 100.00 % MITF 100.00 % PTEN 100.00 % TGFBR2 100.00 %
CACNA1C 100.00 % FOXC1 100.00 % MSX1 100.00 % PTPN11 89.17 % TGIF1 100.00 %
CASK 94.17 % FOXG1 100.00 % MSX2 100.00 % RAI1 100.00 % TIMM8A 100.00 %
CDKN1C 100.00 % FOXL2 100.00 % MTM1 100.00 % RB1 100.00 % TRPS1 100.00 %
CFC1 0.00 % FZD4 100.00 % MYCN 100.00 % RET 100.00 % TSC1 100.00 %
CHD7 100.00 % GATA3 100.00 % NDP 100.00 % RPS19 100.00 % TSC2 98.30 %
CHD8 99.11 % GATA4 100.00 % NDUFV1 100.00 % RS1 100.00 % TWIST1 100.00 %
CHM 95.10 % GDF5 100.00 % NF2 100.00 % RUNX2 100.00 % UPF3B 100.00 %
CHRNA7 84.46 % GJB2 100.00 % NHS 100.00 % SALL1 100.00 % USH1C 100.00 %
CLCNKA 100.00 % GLA 100.00 % NIPBL 100.00 % SALL4 100.00 % VHL 100.00 %
CLCNKB 100.00 % GLI2 100.00 % NLGN4X 100.00 % SATB2 100.00 % WT1 100.00 %
CNTN4 100.00 % GLI3 100.00 % NOTCH2 95.39 % SCN1A 100.00 % XIAP 100.00 %
COL2A1 100.00 % GPC3 100.00 % NR5A1 100.00 % SGCE 94.86 % ZDHHC9 100.00 %
COL4A5 98.76 % GPC6 100.00 % NRXN1 100.00 % SH2D1A 100.00 % ZEB2 100.00 %
CREBBP 100.00 % GPR56 100.00 % NSD1 100.00 % SHANK3 96.32 % ZFPM2 98.84 %
CUL4B 100.00 % GRIA3 100.00 % OCA2 100.00 % SHH 100.00 % ZIC1 100.00 %
CYP21A2 67.67 % HBA1 30.07 % OCRL 100.00 % SIX3 100.00 % ZIC2 100.00 %
DCX 100.00 % HBA2 30.07 % OFD1 100.00 % SLC12A1 100.00 % ZIC3 100.00 %
DHCR7 100.00 % HCCS 100.00 % OTC 91.74 % SLC12A3 100.00 % ZIC4 100.00 %
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for which further evaluation and segregation analysis are
ongoing.
Discussion
The HaloPlex ICCG panel is a pre-designed made-to-
order panel targeting 180 genes. It follows the ICCG rec-
ommendations for design and resolution and is available
through SureDesign from Agilent Technologies. The tar-
geted panel includes genes in the most commonly altered
chromosomal regions according to the ISCA/ICCG data-
base. The 180 genes are covered by 2509 target regions
which range in size from 2 to 6575 nucleotides.
Depending on its size, a region is covered by between 1
and 547 amplicons.
The recommended minimum read depth for clinical
diagnostic sequencing is 20× [15, 16], which was
achieved for over 90 % of the target for 170 genes. For
CHD7, even the exon with the poorest coverage had a
mean of 36 (Fig. 2). Of the remaining ten, four genes
had 80–90 % coverage, and the other six (CFC1,
CYP21A, HBA1, HBA2, IKBKG, NOTCH2, PLP1) had
<80 %. More than half of the targets in these individual
genes are within GC-rich regions. Less efficient PCR for
these templates might have resulted in sequencing fail-
ure during library preparation, or insufficient sequence
data were produced [17]. In addition, the HaloPlex
protocol uses restriction enzymes which are sequence-
dependent and nonrandom, this method might have
contributed further to uneven coverage and also gaps in
coverage [18]. For IKBKG, the presence of a pseudogene
might have caused non-specific alignment and contrib-
uted to the low capture of target sequences [19]. Nijman
et al. have almost no mapped reads in IKBKG in their
targeted sequencing, and generally poor coverage of
CFC1 and IKBKG had been reported in multiple studies
[20–22]. For the gene with the poorest coverage CFC1,
all six exons had no reads across all 15 samples. This
gene is associated with the generation of left-right asym-
metry via the TGF pathway. There were 23 mutations in
HGMD, 13 of which were found in patients with congenital
Fig. 2 Average target base read depth for exons 2–38 of CHD7
Fig. 3 Average target base read depth for exons 1–4 of MECP2
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heart disease [23]. This panel would not be useful for
patients with clinical suspicion of CFC1 gene mutations.
The first exon of 64 genes was not included in the
design (indicated with “*” in Table 2). All the 64
genes have one or more non-coding exon. The entire
exon 1 of these genes (and additional exons for some
others) contains only untranslated regions. In general,
amplification of exon 1 of some genes was problem-
atic because of the generally higher GC content and
sequence complexity [24–26]. Our results showed that
MECP2 had an average target base read depth of
118×. The coverage for exon 1 is the lowest among
all, but it is still two times that of the minimum of
20× recommended for clinical diagnostics (Fig. 3).
SATB2 had an average target base read depth of
300×, but exon 1 was not covered in the design
(Fig. 4). Nevertheless, including non-coding exons in
the design might improve the yield of NGS as vari-
ants affecting splicing of non-coding exons have been
reported to be disease-causing [27].
Many congenital disorders do not have unique and
exclusive features, and the presentations may be non-
specific. Even for syndromic disorders, there are over-
lapping features, and the phenotypic features in some
patients may be atypical, making it challenging for
the clinical geneticists to come to a diagnosis based
on clinical history and examination. All the 15 patients in
this study have constitutional disorders and suspicion of
chromosomal disorders, but CMA did not find any patho-
genic copy number abnormality. With this targeted panel,
Fig. 4 Average target base read depth for exons 2–11 of SATB2
Table 4 Pathogenic variants identified and the respective patients’ associated clinical features
Patient Gender Agea Gene Nucleotide change Amino acid
change
Clinical features
1 M 1d CHD7 NM_017780.3:c.7891C > T p.R2631X Hypoplastic left heart, choanal atresia, oesophageal atresia
2 F 1y4m CHD7 NM_017780.3c.601C > T p.Q201X PDA, aortic stenosis, coloboma, hypotonia
3 F 3y9m MECP2 NM_004992.3:c.763C > T p.R255X Developmental delay, hypotonia, neurodevelopmental regression,
epilepsy
4 F 2w SHH NM_000193.3:c.413C > A p.S138Y Alobar HPE, PDA, hypotelorism, single nostril, choanal atresia,
overlapping fingers
5 M 5y11m TCF4 NM_001083962.1:c.1739G >
A
p.R580Q GDD, microcephaly, epicanthic folds, hypertelorism, drooling, no
speech
6 F 5y8m TSC2 NM_000548.3:c.3364delC p.R1121Vfs*69 Bilateral large renal cysts, ballotable left kidney, cardiac
rhabdomyoma, iris pigmentation & hamartomas, epilepsy
GDD global developmental delay, HPE holoprosencephaly, PDA patent ductus arterio
aAge at enrollment (d = day, y = year, m =month)
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we were able to reach a molecular diagnosis for six
patients after reviewing the results with their primary phy-
sicians (Table 4). Pathogenic CHD7 variants were detected
in two patients with clinical features consistent with
CHARGE syndrome. Both CHD7 variants identified
(p.R2613X and p.Q201X) have been previously reported
in other CHARGE patients [28]. A pathogenic p.R255X
MECP2 variant was detected in a patient with clinical
features of Rett syndrome. This variant has also been re-
ported previously [29]. The patients with the truncating
TSC2 variant and the missense SHH variant also showed
clinical features consistent with the respective causative
genes. These two variants are novel and the missense vari-
ant is predicted to be pathogenic according to both SIFT
and Polyphen. Similarly, the clinical features of the patient
with the TCF4 variant are found to be consistent with
Pitt-Hopkins syndrome upon retrospective review of
the patient’s progressive features by the attending
physician. This p.R580Q TCF4 variant has been re-
ported as pathogenic in patients with Pitt-Hopkins
syndrome [30].
The identification of a patient’s causative mutation has
the translational benefit of providing the parents with an
answer for their child’s condition. In addition, it provides
a guide to the attending clinician on the management and
prognosis of the patient. A molecular diagnosis would also
facilitate access to clinical trials and programs for special
needs children. The use of appropriate gene panels obvi-
ates the need for subjective clinical decision on which
gene(s) to test in each patient, and may lead to a standard
testing workflow for each group of disorders. Generally
for those whose diagnosis can be narrowed down to a
few suspected genetic syndromes, targeted gene
panels would be superior to exome sequencing which
has more limitations in the diagnostic setting due to
coverage deficiencies in some genes and longer turn-
around time. Higher-average read depth could be
attained at a lower cost, making it superior to exome
sequencing in terms of cost, sensitivity, and expected
diagnostic yield [31, 32].
Conclusions
The Haloplex ICCG panel had good coverage except for
ten of the target genes. Consideration would have to be
made for the low coverage for some regions in several
genes which might have to be supplemented by Sanger
sequencing. However, comparing the cost, ease of analysis,
and shorter turnaround time, it is a good alternative to ex-
ome sequencing for patients whose features are suggestive
of a genetic etiology involving one of the genes in the
panel.
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